Are you over 18 and want to see adult content?
More Annotations
Migraine Health Information & Community | Migraine.com
Are you over 18 and want to see adult content?
Die Regensammler: Regentonne, Regentank und mehr
Are you over 18 and want to see adult content?
Download Apps & Games APK Android Free Online | ApkDi.com
Are you over 18 and want to see adult content?
China Munchy Box | China Munchy Box, Bishopmill, Moray, Takeaway Order Online
Are you over 18 and want to see adult content?
GameVicio - Jogos, Tecnologia, Traduções PC, Xbox One, PS4, WII U, 3DS, PSVita - GameVicio
Are you over 18 and want to see adult content?
Le Coin du Salarié: vos droits, votre carrière
Are you over 18 and want to see adult content?
Adil es especialista en vestuario laboral y EPIS - Adil Suministros
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of festivalnaradi.cz
Are you over 18 and want to see adult content?
A complete backup of pamellas.livejournal.com
Are you over 18 and want to see adult content?
A complete backup of cclitier.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of pelgranepress.com
Are you over 18 and want to see adult content?
A complete backup of recyclingsimplified.com
Are you over 18 and want to see adult content?
Text
CODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and GET HELP WITH YOUR PRESCRIPTIONS Navigating the complexities of today’s health care system can be confusing and overwhelming, but it doesn’t have to be. America’s biopharmaceutical research companies that make up PhRMA have partnered with health care providers, pharmacists, patient advocacy organizations and community groups to help patients afford their medicines by creating the Medicine Assistance Tool (MAT). CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by H.R. 3 IS THE WRONG APPROACH FOR AMERICA H.R. 3 is the wrong approach for patients and the U.S. health care system. Instead, we need to take a holistic approach to lowering patient costs while supporting medical innovation and ensuring Americans have access to the best treatments available. Learn more about the negative impacts of H.R. 3. Impact on Access to TreatmentsImpact on
PRINCIPLES ON CONDUCT OF CLINICAL TRIALS PhRMA Principles on Conduct of Clinical Trials. Developing new therapies to treat disease and to improve quality of life is a long and complex process. A critical part of that process is clinical research, the study of a pharmaceutical product in humans. Without clinical research studies, no new medicines could be made available topatients.
DEBRA DESHONG, PHRMA Debra DeShong is Executive Vice President of Public Affairs for the Pharmaceutical Research and Manufacturers of America (PhRMA)—the trade association representing the country’s leading biopharmaceutical research companies. At PhRMA, Ms. DeShong is responsible for developing and executing the overall communicationsstrategy for the
CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in ALEXANDER HARDY, GENENTECH Alexander Hardy became Genentech’s Chief Executive Officer March 1, 2019. Previously, he was head of Global Product Strategy, Roche Pharmaceuticals and served in a number of key leadership positions across Genentech and Roche for over 13 years. Alexander led cross-functional teams to develop and launch new medicines andindications in more
PHRMA ORG | PHRMAMEMBERS SITEEVENTSSTAY CONNECTEDBLOGDRUG DISCOVERYHOMEPAGE HEADER BAR Working Together to Fight COVID-19. The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchersCODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and GET HELP WITH YOUR PRESCRIPTIONS Navigating the complexities of today’s health care system can be confusing and overwhelming, but it doesn’t have to be. America’s biopharmaceutical research companies that make up PhRMA have partnered with health care providers, pharmacists, patient advocacy organizations and community groups to help patients afford their medicines by creating the Medicine Assistance Tool (MAT). CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by H.R. 3 IS THE WRONG APPROACH FOR AMERICA H.R. 3 is the wrong approach for patients and the U.S. health care system. Instead, we need to take a holistic approach to lowering patient costs while supporting medical innovation and ensuring Americans have access to the best treatments available. Learn more about the negative impacts of H.R. 3. Impact on Access to TreatmentsImpact on
PRINCIPLES ON CONDUCT OF CLINICAL TRIALS PhRMA Principles on Conduct of Clinical Trials. Developing new therapies to treat disease and to improve quality of life is a long and complex process. A critical part of that process is clinical research, the study of a pharmaceutical product in humans. Without clinical research studies, no new medicines could be made available topatients.
DEBRA DESHONG, PHRMA Debra DeShong is Executive Vice President of Public Affairs for the Pharmaceutical Research and Manufacturers of America (PhRMA)—the trade association representing the country’s leading biopharmaceutical research companies. At PhRMA, Ms. DeShong is responsible for developing and executing the overall communicationsstrategy for the
CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in ALEXANDER HARDY, GENENTECH Alexander Hardy became Genentech’s Chief Executive Officer March 1, 2019. Previously, he was head of Global Product Strategy, Roche Pharmaceuticals and served in a number of key leadership positions across Genentech and Roche for over 13 years. Alexander led cross-functional teams to develop and launch new medicines andindications in more
ABOUT | PHRMA
About. The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventions MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by PHRMA STATEMENT ON HOUSE LEADERSHIP’S “PARTISAN” DRUG WASHINGTON, D.C. (April 22, 2021) – Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl issued the following statement today after House Democratic leaders released their partisan drug pricing proposal: “The American people want to end the pandemic, get the economy back on track and make health care more affordable and predictable. COVID-19 VACCINES AND THE ROAD AHEAD| PHRMA From delaying medical care and putting off doctor visits, to struggling to access adequate services ‒ health care in the traditional sense had largely been put on hold during the COVID-19 pandemic. But now, as vaccines bring hope that the nation may soon begin to emerge from this crisis, longstanding concerns will have to be addressed. High out-of-pocket costs and surprise medical billsCHART PACKS
Chart Pack: Biopharmaceuticals in Perspective, Fall 2020. This chart pack provides facts and figures about prescription medicines and their role in the health care system. Data and information in this publication were drawn from a wide range of sources, including PRINCIPLES ON INTERACTIONS WITH PATIENT ORGANIZATIONS PhRMA Principles on Interactions with Patient Organizations. Biopharmaceutical companies share many common interests with patient organizations including, most importantly, a common commitment to patients and shared mission to discover cures and fight disease. In our joint mission of innovation and service to patients and caregivers, companies FOLLOW THE DOLLAR REPORT Follow the Dollar Report. This paper provides a high-level explanation of the financial flows that occur as brand medicines move through the supply chain for retail, mail-order and specialty drugs. Download the Executive Summary. Download the Report. -. CODE ON INTERACTIONS WITH HEALTH CARE PROFESSIONALS This Code reflects and builds upon the standards and principles set forth in its predecessor, the PhRMA Code on Interactions with Health Care Professionals that took effect in January 2009. Like the 2009 edition, this Code addresses interactions with respect to marketed products and related pre-launch activities. BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitateCODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventions MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of PHRMA STATEMENT ON HOUSE LEADERSHIP’S “PARTISAN” DRUG PhRMA Statement on House Leadership’s “Partisan” Drug Pricing Proposal. WASHINGTON, D.C. (April 22, 2021) – Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl issued the following statement today after House Democratic leaders released their partisan drug pricing proposal: “The American peoplewant
FOLLOW THE DOLLAR REPORT Follow the Dollar Report. This paper provides a high-level explanation of the financial flows that occur as brand medicines move through the supply chain for retail, mail-order and specialty drugs. Download the Executive Summary. Download the Report. -. BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in BIOPHARMACEUTICAL RESEARCH & DEVELOPMENT phase i phase ii phase iii phase iv ind submitted tens number of volunteers hundreds thousands nda/bla submitted fda approval the biopharmaceutical research and development process INNOVATIVE CONTRACTING: OPPORTUNITIES AND CHALLENGES INNOVATIVE CONTRACTS CAN BE BENEFICIAL TO PATIENTS AND LOWER OUT-OF-POCKET COSTS WHILE PROVIDING SAVINGS FOR THE HEALTH SYSTEM. 1 Avalere. More than Half of Health Plans Use Outcomes-Based Contracts.CODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventions MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of PHRMA STATEMENT ON HOUSE LEADERSHIP’S “PARTISAN” DRUG PhRMA Statement on House Leadership’s “Partisan” Drug Pricing Proposal. WASHINGTON, D.C. (April 22, 2021) – Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl issued the following statement today after House Democratic leaders released their partisan drug pricing proposal: “The American peoplewant
FOLLOW THE DOLLAR REPORT Follow the Dollar Report. This paper provides a high-level explanation of the financial flows that occur as brand medicines move through the supply chain for retail, mail-order and specialty drugs. Download the Executive Summary. Download the Report. -. BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in BIOPHARMACEUTICAL RESEARCH & DEVELOPMENT phase i phase ii phase iii phase iv ind submitted tens number of volunteers hundreds thousands nda/bla submitted fda approval the biopharmaceutical research and development process INNOVATIVE CONTRACTING: OPPORTUNITIES AND CHALLENGES INNOVATIVE CONTRACTS CAN BE BENEFICIAL TO PATIENTS AND LOWER OUT-OF-POCKET COSTS WHILE PROVIDING SAVINGS FOR THE HEALTH SYSTEM. 1 Avalere. More than Half of Health Plans Use Outcomes-Based Contracts.PHRMA ORG | PHRMA
Working Together to Fight COVID-19. The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by GET HELP WITH YOUR PRESCRIPTIONS Navigating the complexities of today’s health care system can be confusing and overwhelming, but it doesn’t have to be. America’s biopharmaceutical research companies that make up PhRMA have partnered with health care providers, pharmacists, patient advocacy organizations and community groups to help patients afford their medicines by creating the Medicine Assistance Tool (MAT). PHRMA STATEMENT ON HOUSE LEADERSHIP’S “PARTISAN” DRUG WASHINGTON, D.C. (April 22, 2021) – Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl issued the following statement today after House Democratic leaders released their partisan drug pricing proposal: “The American people want to end the pandemic, get the economy back on track and make health care more affordable and predictable.ACCESS TO MEDICINES
Patient access to the medicines they need is critical both for individuals and for our health care system more broadly. In the United States, patients can access medicines a number of ways, including through employer-sponsored health plan, a health insurance exchange plan or a program like Medicare or Medicaid. Today, Americans havefaster
COMING TOGETHER TO FIGHT COVID-19: A CONVERSATION WITH Stephen J. Ubl Stephen J. Ubl is president and chief executive officer of PhRMA. Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. PRINCIPLES ON CONDUCT OF CLINICAL TRIALS PhRMA Principles on Conduct of Clinical Trials. Developing new therapies to treat disease and to improve quality of life is a long and complex process. A critical part of that process is clinical research, the study of a pharmaceutical product in humans. Without clinical research studies, no new medicines could be made available topatients.
INFOGRAPHICS ON OBTAINING PATENTS AND MAINTAINING PATENTS Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. The U.S. patent system provides critical incentives for innovation and fuels the creation of new medicines. Yet, there can be confusion around what it takes for a patent to be granted and maintained. These two HOW RESEARCH EVOLVES AND BRINGS NEW HOPE TO PATIENTS Stephen J. Ubl Stephen J. Ubl is president and chief executive officer of PhRMA. Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. CONTINUED R&D INTO ALZHEIMER’S DISEASE MEANS HOPE FOR More than 6 million Americans, most of them age 65 or older, live with Alzheimer’s disease, a devastating degenerative brain disease and the most common form of dementia. Despite the immense challenges to research, biopharmaceutical companies remain committed. PHRMA ORG | PHRMAMEMBERS SITEEVENTSSTAY CONNECTEDBLOGDRUG DISCOVERYHOMEPAGE HEADER BAR Working Together to Fight COVID-19. The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers and biotechnology companies.CODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventions MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of COVID-19 VACCINES AND THE ROAD AHEAD| PHRMA From delaying medical care and putting off doctor visits, to struggling to access adequate services ‒ health care in the traditional sense had largely been put on hold during the COVID-19 pandemic. But now, as vaccines bring hope that the nation may soon begin to emerge from this crisis, longstanding concerns will have to be addressed. High out-of-pocket costs and surprise medical bills CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in ALEXANDER HARDY, GENENTECH Alexander Hardy became Genentech’s Chief Executive Officer March 1, 2019. Previously, he was head of Global Product Strategy, Roche Pharmaceuticals and served in a number of key leadership positions across Genentech and Roche for over 13 years. Alexander led cross-functional teams to develop and launch new medicines andindications in more
BIOPHARMACEUTICAL RESEARCH & DEVELOPMENT phase i phase ii phase iii phase iv ind submitted tens number of volunteers hundreds thousands nda/bla submitted fda approval the biopharmaceutical research and development process INNOVATIVE CONTRACTING: OPPORTUNITIES AND CHALLENGES INNOVATIVE CONTRACTS CAN BE BENEFICIAL TO PATIENTS AND LOWER OUT-OF-POCKET COSTS WHILE PROVIDING SAVINGS FOR THE HEALTH SYSTEM. 1 Avalere. More than Half of Health Plans Use Outcomes-Based Contracts. PHRMA ORG | PHRMAMEMBERS SITEEVENTSSTAY CONNECTEDBLOGDRUG DISCOVERYHOMEPAGE HEADER BAR Working Together to Fight COVID-19. The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers and biotechnology companies.CODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventions MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of COVID-19 VACCINES AND THE ROAD AHEAD| PHRMA From delaying medical care and putting off doctor visits, to struggling to access adequate services ‒ health care in the traditional sense had largely been put on hold during the COVID-19 pandemic. But now, as vaccines bring hope that the nation may soon begin to emerge from this crisis, longstanding concerns will have to be addressed. High out-of-pocket costs and surprise medical bills CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in ALEXANDER HARDY, GENENTECH Alexander Hardy became Genentech’s Chief Executive Officer March 1, 2019. Previously, he was head of Global Product Strategy, Roche Pharmaceuticals and served in a number of key leadership positions across Genentech and Roche for over 13 years. Alexander led cross-functional teams to develop and launch new medicines andindications in more
BIOPHARMACEUTICAL RESEARCH & DEVELOPMENT phase i phase ii phase iii phase iv ind submitted tens number of volunteers hundreds thousands nda/bla submitted fda approval the biopharmaceutical research and development process INNOVATIVE CONTRACTING: OPPORTUNITIES AND CHALLENGES INNOVATIVE CONTRACTS CAN BE BENEFICIAL TO PATIENTS AND LOWER OUT-OF-POCKET COSTS WHILE PROVIDING SAVINGS FOR THE HEALTH SYSTEM. 1 Avalere. More than Half of Health Plans Use Outcomes-Based Contracts. PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventionsABOUT | PHRMA
About. The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 COVID-19 VACCINES AND THE ROAD AHEAD| PHRMA From delaying medical care and putting off doctor visits, to struggling to access adequate services ‒ health care in the traditional sense had largely been put on hold during the COVID-19 pandemic. But now, as vaccines bring hope that the nation may soon begin to emerge from this crisis, longstanding concerns will have to be addressed. High out-of-pocket costs and surprise medical billsACCESS TO MEDICINES
Patient access to the medicines they need is critical both for individuals and for our health care system more broadly. In the United States, patients can access medicines a number of ways, including through employer-sponsored health plan, a health insurance exchange plan or a program like Medicare or Medicaid. Today, Americans havefaster
REPORT: NEARLY 90 MEDICINES IN DEVELOPMENT AGAINST DRUG Medicines in Development for Antimicrobial Resistance (AMR) 2021 Report. As the world confronts the COVID-19 public health crisis, now more than ever is the time to consider preparedness for a growing public health threat: antimicrobial resistance (AMR). AMR is a natural process that occurs when microorganisms such as bacteria, viruses,fungi
H.R. 3 IS THE WRONG APPROACH FOR AMERICA H.R. 3 is the wrong approach for patients and the U.S. health care system. Instead, we need to take a holistic approach to lowering patient costs while supporting medical innovation and ensuring Americans have access to the best treatments available. Learn more about the negative impacts of H.R. 3. Impact on Access to TreatmentsImpact on
PHRMA STATEMENT ON HOUSE LEADERSHIP’S “PARTISAN” DRUG WASHINGTON, D.C. (April 22, 2021) – Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl issued the following statement today after House Democratic leaders released their partisan drug pricing proposal: “The American people want to end the pandemic, get the economy back on track and make health care more affordable and predictable. COMING TOGETHER TO FIGHT COVID-19: A CONVERSATION WITH Stephen J. Ubl Stephen J. Ubl is president and chief executive officer of PhRMA. Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate RESEARCHING ALZHEIMER’S MEDICINES Society’s Great Challenge More than 6 million Americans impacted 6th leading cause of death in the U.S. $355 billion each year in direct medical costs More than 11 million caregivers providing $257 billion in uncompensated care Black Americans are twice as likely and Latinos are 1.5 times more likely to develop Alzheimer’s than non-Hispanicwhite Americans
PHRMA ORG | PHRMAMEMBERS SITEEVENTSSTAY CONNECTEDBLOGDRUG DISCOVERYHOMEPAGE HEADER BAR Working Together to Fight COVID-19. The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers and biotechnology companies.CODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventions MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of COVID-19 VACCINES AND THE ROAD AHEAD| PHRMA From delaying medical care and putting off doctor visits, to struggling to access adequate services ‒ health care in the traditional sense had largely been put on hold during the COVID-19 pandemic. But now, as vaccines bring hope that the nation may soon begin to emerge from this crisis, longstanding concerns will have to be addressed. High out-of-pocket costs and surprise medical bills CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in ALEXANDER HARDY, GENENTECH Alexander Hardy became Genentech’s Chief Executive Officer March 1, 2019. Previously, he was head of Global Product Strategy, Roche Pharmaceuticals and served in a number of key leadership positions across Genentech and Roche for over 13 years. Alexander led cross-functional teams to develop and launch new medicines andindications in more
BIOPHARMACEUTICAL RESEARCH & DEVELOPMENT phase i phase ii phase iii phase iv ind submitted tens number of volunteers hundreds thousands nda/bla submitted fda approval the biopharmaceutical research and development process INNOVATIVE CONTRACTING: OPPORTUNITIES AND CHALLENGES INNOVATIVE CONTRACTS CAN BE BENEFICIAL TO PATIENTS AND LOWER OUT-OF-POCKET COSTS WHILE PROVIDING SAVINGS FOR THE HEALTH SYSTEM. 1 Avalere. More than Half of Health Plans Use Outcomes-Based Contracts. PHRMA ORG | PHRMAMEMBERS SITEEVENTSSTAY CONNECTEDBLOGDRUG DISCOVERYHOMEPAGE HEADER BAR Working Together to Fight COVID-19. The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers and biotechnology companies.CODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventions MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of COVID-19 VACCINES AND THE ROAD AHEAD| PHRMA From delaying medical care and putting off doctor visits, to struggling to access adequate services ‒ health care in the traditional sense had largely been put on hold during the COVID-19 pandemic. But now, as vaccines bring hope that the nation may soon begin to emerge from this crisis, longstanding concerns will have to be addressed. High out-of-pocket costs and surprise medical bills CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in ALEXANDER HARDY, GENENTECH Alexander Hardy became Genentech’s Chief Executive Officer March 1, 2019. Previously, he was head of Global Product Strategy, Roche Pharmaceuticals and served in a number of key leadership positions across Genentech and Roche for over 13 years. Alexander led cross-functional teams to develop and launch new medicines andindications in more
BIOPHARMACEUTICAL RESEARCH & DEVELOPMENT phase i phase ii phase iii phase iv ind submitted tens number of volunteers hundreds thousands nda/bla submitted fda approval the biopharmaceutical research and development process INNOVATIVE CONTRACTING: OPPORTUNITIES AND CHALLENGES INNOVATIVE CONTRACTS CAN BE BENEFICIAL TO PATIENTS AND LOWER OUT-OF-POCKET COSTS WHILE PROVIDING SAVINGS FOR THE HEALTH SYSTEM. 1 Avalere. More than Half of Health Plans Use Outcomes-Based Contracts. PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventionsABOUT | PHRMA
About. The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 COVID-19 VACCINES AND THE ROAD AHEAD| PHRMA From delaying medical care and putting off doctor visits, to struggling to access adequate services ‒ health care in the traditional sense had largely been put on hold during the COVID-19 pandemic. But now, as vaccines bring hope that the nation may soon begin to emerge from this crisis, longstanding concerns will have to be addressed. High out-of-pocket costs and surprise medical billsACCESS TO MEDICINES
Patient access to the medicines they need is critical both for individuals and for our health care system more broadly. In the United States, patients can access medicines a number of ways, including through employer-sponsored health plan, a health insurance exchange plan or a program like Medicare or Medicaid. Today, Americans havefaster
REPORT: NEARLY 90 MEDICINES IN DEVELOPMENT AGAINST DRUG Medicines in Development for Antimicrobial Resistance (AMR) 2021 Report. As the world confronts the COVID-19 public health crisis, now more than ever is the time to consider preparedness for a growing public health threat: antimicrobial resistance (AMR). AMR is a natural process that occurs when microorganisms such as bacteria, viruses,fungi
H.R. 3 IS THE WRONG APPROACH FOR AMERICA H.R. 3 is the wrong approach for patients and the U.S. health care system. Instead, we need to take a holistic approach to lowering patient costs while supporting medical innovation and ensuring Americans have access to the best treatments available. Learn more about the negative impacts of H.R. 3. Impact on Access to TreatmentsImpact on
PHRMA STATEMENT ON HOUSE LEADERSHIP’S “PARTISAN” DRUG WASHINGTON, D.C. (April 22, 2021) – Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl issued the following statement today after House Democratic leaders released their partisan drug pricing proposal: “The American people want to end the pandemic, get the economy back on track and make health care more affordable and predictable. COMING TOGETHER TO FIGHT COVID-19: A CONVERSATION WITH Stephen J. Ubl Stephen J. Ubl is president and chief executive officer of PhRMA. Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate RESEARCHING ALZHEIMER’S MEDICINES Society’s Great Challenge More than 6 million Americans impacted 6th leading cause of death in the U.S. $355 billion each year in direct medical costs More than 11 million caregivers providing $257 billion in uncompensated care Black Americans are twice as likely and Latinos are 1.5 times more likely to develop Alzheimer’s than non-Hispanicwhite Americans
CODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventions CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by GET HELP WITH YOUR PRESCRIPTIONS Navigating the complexities of today’s health care system can be confusing and overwhelming, but it doesn’t have to be. America’s biopharmaceutical research companies that make up PhRMA have partnered with health care providers, pharmacists, patient advocacy organizations and community groups to help patients afford their medicines by creating the Medicine Assistance Tool (MAT). REPORT: INDUSTRY PROFILE 2019 Industry Profile 2019. To download the full report, click here. The Profile is PhRMA’s flagship publication for telling the story of the sector for nearly five decades. It outlines what the industry stands for—including key policy solutions—along with an advocacy toolkiton key issue areas.
FOLLOW THE DOLLAR REPORT Follow the Dollar Report. This paper provides a high-level explanation of the financial flows that occur as brand medicines move through the supply chain for retail, mail-order and specialty drugs. Download the Executive Summary. Download the Report. -. BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in BIOPHARMACEUTICAL RESEARCH & DEVELOPMENT phase i phase ii phase iii phase iv ind submitted tens number of volunteers hundreds thousands nda/bla submitted fda approval the biopharmaceutical research and development processCODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventions CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by GET HELP WITH YOUR PRESCRIPTIONS Navigating the complexities of today’s health care system can be confusing and overwhelming, but it doesn’t have to be. America’s biopharmaceutical research companies that make up PhRMA have partnered with health care providers, pharmacists, patient advocacy organizations and community groups to help patients afford their medicines by creating the Medicine Assistance Tool (MAT). REPORT: INDUSTRY PROFILE 2019 Industry Profile 2019. To download the full report, click here. The Profile is PhRMA’s flagship publication for telling the story of the sector for nearly five decades. It outlines what the industry stands for—including key policy solutions—along with an advocacy toolkiton key issue areas.
FOLLOW THE DOLLAR REPORT Follow the Dollar Report. This paper provides a high-level explanation of the financial flows that occur as brand medicines move through the supply chain for retail, mail-order and specialty drugs. Download the Executive Summary. Download the Report. -. BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in BIOPHARMACEUTICAL RESEARCH & DEVELOPMENT phase i phase ii phase iii phase iv ind submitted tens number of volunteers hundreds thousands nda/bla submitted fda approval the biopharmaceutical research and development processPHRMA ORG | PHRMA
Working Together to Fight COVID-19. The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers and biotechnology companies. MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by GET HELP WITH YOUR PRESCRIPTIONS Navigating the complexities of today’s health care system can be confusing and overwhelming, but it doesn’t have to be. America’s biopharmaceutical research companies that make up PhRMA have partnered with health care providers, pharmacists, patient advocacy organizations and community groups to help patients afford their medicines by creating the Medicine Assistance Tool (MAT).ACCESS TO MEDICINES
Patient access to the medicines they need is critical both for individuals and for our health care system more broadly. In the United States, patients can access medicines a number of ways, including through employer-sponsored health plan, a health insurance exchange plan or a program like Medicare or Medicaid. Today, Americans havefaster
BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate COMING TOGETHER TO FIGHT COVID-19: A CONVERSATION WITH Stephen J. Ubl Stephen J. Ubl is president and chief executive officer of PhRMA. Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. INFOGRAPHICS ON OBTAINING PATENTS AND MAINTAINING PATENTS Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. The U.S. patent system provides critical incentives for innovation and fuels the creation of new medicines. Yet, there can be confusion around what it takes for a patent to be granted and maintained. These two STATEMENT ON APPLICATION OF PHRMA CODE SECTION 2 DURING 1 Statement on Application of PhRMA Code Section 2 During Emergency Periods June 30, 2020 Biopharmaceutical company representatives play an important role in delivering accurate, up-to- RESEARCHING ALZHEIMER’S MEDICINES Society’s Great Challenge More than 6 million Americans impacted 6th leading cause of death in the U.S. $355 billion each year in direct medical costs More than 11 million caregivers providing $257 billion in uncompensated care Black Americans are twice as likely and Latinos are 1.5 times more likely to develop Alzheimer’s than non-Hispanicwhite Americans
NEW REPORTS SHED LIGHT ON KEY FACTS ABOUT MEDICINES AND A recently released report by IQVIA – an independent organization specializing in health care research – provides new data showing prices for brand medicines went down last year. The report offers important facts to keep in mind as policymakers look to make health care more affordable. According to the report: Net prices for brand medicines declined by 2.9%, on average, in 2020, and net PHRMA ORG | PHRMAMEMBERS SITEEVENTSSTAY CONNECTEDBLOGDRUG DISCOVERYHOMEPAGE HEADER BAR Working Together to Fight COVID-19. The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers and biotechnology companies.CODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and GET HELP WITH YOUR PRESCRIPTIONS Navigating the complexities of today’s health care system can be confusing and overwhelming, but it doesn’t have to be. America’s biopharmaceutical research companies that make up PhRMA have partnered with health care providers, pharmacists, patient advocacy organizations and community groups to help patients afford their medicines by creating the Medicine Assistance Tool (MAT). BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate CODE ON INTERACTIONS WITH HEALTH CARE PROFESSIONALS This Code reflects and builds upon the standards and principles set forth in its predecessor, the PhRMA Code on Interactions with Health Care Professionals that took effect in January 2009. Like the 2009 edition, this Code addresses interactions with respect to marketed products and related pre-launch activities.STEPHEN J UBL
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies.The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually -- more than any other industry in CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in STATEMENT ON APPLICATION OF PHRMA CODE SECTION 2 DURING 1 Statement on Application of PhRMA Code Section 2 During Emergency Periods June 30, 2020 Biopharmaceutical company representatives play an important role in delivering accurate, up-to-RICHARD MOSCICKI MD
Richard (Rich) A. Moscicki (Mo-shis-ke), M.D., is the executive vice president of science and regulatory advocacy and the chief medical officer at the Pharmaceutical Research and Manufacturers of America (PhRMA). Dr. Moscicki came to PhRMA in 2017 after serving as the deputy center director for science operations for the U.S. Food andDrug
PREA AND BPCA
PREA AND BPCA: SPURRING PEDIATRIC DRUG DEVELOPMENT HISTORIC CHALLENGE: Prior to 1997, which is when the first pediatric drug development incentive legislation was enacted as part PHRMA ORG | PHRMAMEMBERS SITEEVENTSSTAY CONNECTEDBLOGDRUG DISCOVERYHOMEPAGE HEADER BAR Working Together to Fight COVID-19. The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers and biotechnology companies.CODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and GET HELP WITH YOUR PRESCRIPTIONS Navigating the complexities of today’s health care system can be confusing and overwhelming, but it doesn’t have to be. America’s biopharmaceutical research companies that make up PhRMA have partnered with health care providers, pharmacists, patient advocacy organizations and community groups to help patients afford their medicines by creating the Medicine Assistance Tool (MAT). BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate CODE ON INTERACTIONS WITH HEALTH CARE PROFESSIONALS This Code reflects and builds upon the standards and principles set forth in its predecessor, the PhRMA Code on Interactions with Health Care Professionals that took effect in January 2009. Like the 2009 edition, this Code addresses interactions with respect to marketed products and related pre-launch activities.STEPHEN J UBL
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies.The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually -- more than any other industry in CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in STATEMENT ON APPLICATION OF PHRMA CODE SECTION 2 DURING 1 Statement on Application of PhRMA Code Section 2 During Emergency Periods June 30, 2020 Biopharmaceutical company representatives play an important role in delivering accurate, up-to-RICHARD MOSCICKI MD
Richard (Rich) A. Moscicki (Mo-shis-ke), M.D., is the executive vice president of science and regulatory advocacy and the chief medical officer at the Pharmaceutical Research and Manufacturers of America (PhRMA). Dr. Moscicki came to PhRMA in 2017 after serving as the deputy center director for science operations for the U.S. Food andDrug
PREA AND BPCA
PREA AND BPCA: SPURRING PEDIATRIC DRUG DEVELOPMENT HISTORIC CHALLENGE: Prior to 1997, which is when the first pediatric drug development incentive legislation was enacted as partABOUT | PHRMA
About. The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventionsIN THE PIPELINE
With more than 8,000 medicines in development, 74% of which are potentially first-in-class, patients have more reasons to be optimistic than ever before. Medicines and vaccines are being developed across dozens of therapeutic areas – including COVID-19, cancer, diabetes, cardiovascular, Alzheimer’s disease and MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate REPORT: INDUSTRY PROFILE 2019 Industry Profile 2019. To download the full report, click here. The Profile is PhRMA’s flagship publication for telling the story of the sector for nearly five decades. It outlines what the industry stands for—including key policy solutions—along with an advocacy toolkiton key issue areas.
CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of DIRECT TO CONSUMER ADVERTISING PRINCIPLES Direct to Consumer Advertising Principles. In October 2018, PhRMA’s Board of Directors adopted measures to enhance the PhRMA Guiding Principles on Direct to Consumer Advertisements about Prescription Medicines. The revised, voluntary Principles become effective on April 15, 2019 and include a new guiding principle stating that “ llDTC
RESEARCHING ALZHEIMER’S MEDICINES Society’s Great Challenge More than 6 million Americans impacted 6th leading cause of death in the U.S. $355 billion each year in direct medical costs More than 11 million caregivers providing $257 billion in uncompensated care Black Americans are twice as likely and Latinos are 1.5 times more likely to develop Alzheimer’s than non-Hispanicwhite Americans
JAMES C STANSEL
James C. Stansel is executive vice president, general counsel and corporate secretary of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he is responsible for leading a team of lawyers in supporting PhRMA’s policy, advocacy and science priorities and in the development of sound legal policies impacting the pharmaceutical industry. PHRMA ORG | PHRMAMEMBERS SITEEVENTSSTAY CONNECTEDBLOGDRUG DISCOVERYHOMEPAGE HEADER BAR Working Together to Fight COVID-19. The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers and biotechnology companies.CODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and GET HELP WITH YOUR PRESCRIPTIONS Navigating the complexities of today’s health care system can be confusing and overwhelming, but it doesn’t have to be. America’s biopharmaceutical research companies that make up PhRMA have partnered with health care providers, pharmacists, patient advocacy organizations and community groups to help patients afford their medicines by creating the Medicine Assistance Tool (MAT). BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate CODE ON INTERACTIONS WITH HEALTH CARE PROFESSIONALS This Code reflects and builds upon the standards and principles set forth in its predecessor, the PhRMA Code on Interactions with Health Care Professionals that took effect in January 2009. Like the 2009 edition, this Code addresses interactions with respect to marketed products and related pre-launch activities.STEPHEN J UBL
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies.The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually -- more than any other industry in CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in STATEMENT ON APPLICATION OF PHRMA CODE SECTION 2 DURING 1 Statement on Application of PhRMA Code Section 2 During Emergency Periods June 30, 2020 Biopharmaceutical company representatives play an important role in delivering accurate, up-to-RICHARD MOSCICKI MD
Richard (Rich) A. Moscicki (Mo-shis-ke), M.D., is the executive vice president of science and regulatory advocacy and the chief medical officer at the Pharmaceutical Research and Manufacturers of America (PhRMA). Dr. Moscicki came to PhRMA in 2017 after serving as the deputy center director for science operations for the U.S. Food andDrug
PREA AND BPCA
PREA AND BPCA: SPURRING PEDIATRIC DRUG DEVELOPMENT HISTORIC CHALLENGE: Prior to 1997, which is when the first pediatric drug development incentive legislation was enacted as part PHRMA ORG | PHRMAMEMBERS SITEEVENTSSTAY CONNECTEDBLOGDRUG DISCOVERYHOMEPAGE HEADER BAR Working Together to Fight COVID-19. The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers and biotechnology companies.CODES & GUIDELINES
Codes & Guidelines. PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and GET HELP WITH YOUR PRESCRIPTIONS Navigating the complexities of today’s health care system can be confusing and overwhelming, but it doesn’t have to be. America’s biopharmaceutical research companies that make up PhRMA have partnered with health care providers, pharmacists, patient advocacy organizations and community groups to help patients afford their medicines by creating the Medicine Assistance Tool (MAT). BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate CODE ON INTERACTIONS WITH HEALTH CARE PROFESSIONALS This Code reflects and builds upon the standards and principles set forth in its predecessor, the PhRMA Code on Interactions with Health Care Professionals that took effect in January 2009. Like the 2009 edition, this Code addresses interactions with respect to marketed products and related pre-launch activities.STEPHEN J UBL
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies.The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually -- more than any other industry in CODE ON INTERACTIONS Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. health care professionals. This Code reflects and builds upon the standards and principles set forth in STATEMENT ON APPLICATION OF PHRMA CODE SECTION 2 DURING 1 Statement on Application of PhRMA Code Section 2 During Emergency Periods June 30, 2020 Biopharmaceutical company representatives play an important role in delivering accurate, up-to-RICHARD MOSCICKI MD
Richard (Rich) A. Moscicki (Mo-shis-ke), M.D., is the executive vice president of science and regulatory advocacy and the chief medical officer at the Pharmaceutical Research and Manufacturers of America (PhRMA). Dr. Moscicki came to PhRMA in 2017 after serving as the deputy center director for science operations for the U.S. Food andDrug
PREA AND BPCA
PREA AND BPCA: SPURRING PEDIATRIC DRUG DEVELOPMENT HISTORIC CHALLENGE: Prior to 1997, which is when the first pediatric drug development incentive legislation was enacted as partABOUT | PHRMA
About. The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 PHRMA’S EQUITY INITIATIVE PhRMA CAREs Grant: Addressing Racial Disparities in Medication Utilization and Adherence. In 2019, PhRMA established the Health Equity Roundtable with the goal of improving health outcomes by addressing inequities in care. As part of the Health Equity Roundtable, PhRMA is offering funding opportunities to spur ideas for practical interventionsIN THE PIPELINE
With more than 8,000 medicines in development, 74% of which are potentially first-in-class, patients have more reasons to be optimistic than ever before. Medicines and vaccines are being developed across dozens of therapeutic areas – including COVID-19, cancer, diabetes, cardiovascular, Alzheimer’s disease and MEDICINES IN DEVELOPMENT Medicines in Development for Antimicrobial Resistance 2021 Report. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by BIOPHARMACEUTICAL DIGITAL HEALTH LEXICON Digital health is transforming nearly every aspect of our health care system, improving efficiency, expanding access to treatments and technologies, and ushering in increased development of personalized medicine. One of the foundational elements of a modern digital R&D regulatory framework is a common lexicon and understanding of key terms to orient stakeholders and facilitate REPORT: INDUSTRY PROFILE 2019 Industry Profile 2019. To download the full report, click here. The Profile is PhRMA’s flagship publication for telling the story of the sector for nearly five decades. It outlines what the industry stands for—including key policy solutions—along with an advocacy toolkiton key issue areas.
CLINICAL TRIAL DIVERSITY Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps. Understanding the challenges of DIRECT TO CONSUMER ADVERTISING PRINCIPLES Direct to Consumer Advertising Principles. In October 2018, PhRMA’s Board of Directors adopted measures to enhance the PhRMA Guiding Principles on Direct to Consumer Advertisements about Prescription Medicines. The revised, voluntary Principles become effective on April 15, 2019 and include a new guiding principle stating that “ llDTC
RESEARCHING ALZHEIMER’S MEDICINES Society’s Great Challenge More than 6 million Americans impacted 6th leading cause of death in the U.S. $355 billion each year in direct medical costs More than 11 million caregivers providing $257 billion in uncompensated care Black Americans are twice as likely and Latinos are 1.5 times more likely to develop Alzheimer’s than non-Hispanicwhite Americans
JAMES C STANSEL
James C. Stansel is executive vice president, general counsel and corporate secretary of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he is responsible for leading a team of lawyers in supporting PhRMA’s policy, advocacy and science priorities and in the development of sound legal policies impacting the pharmaceutical industry. PhRMA LogoPhRMA logo with words Research, Progress, and Hopeunderneath
* Our Network
Welcome to the future of medicine. Where together, we go boldly.__Learn More
Learn more about America's biopharmaceutical companies and how they seek to improve patients' lives.__Learn More
A search engine designed to find resources available through the various biopharmaceutical industry programs.__Learn More
Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.__Learn More
There are right and wrong prescriptions for changing Medicare. Seniors need Washington to focus on the right ones.__Learn More
The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.__Learn More
We Work For Health aims to increase awareness by uniting workers throughout the industry.__Learn More
* Members Site
* Press Room
* Events
* Stay Connected
STAY CONNECTED
__
__
__
__
__
SIGN UP FOR UPDATES
__
*
SEARCH THE PHRMA NETWORK__
PhRMA LogoPhRMA logo with words Research, Progress, and Hopeunderneath
* About
Overview Our MissionOur Leadership
Members
Careers Events
Codes and GuidelinesABOUT
PhRMA represents the country’s leading biopharmaceutical research companies and supports the search for new treatments and cures. Policy Solutions | PhRMA Industry Profile 2019 | PhRMA* Advocacy
Overview
Access to Medicines
Overview Insurance CoverageMedicare
Access Better CoveragePatient Assistance
Medicaid
340B Drug Pricing
Program
Cost and Value of Medicines Overview Let's Talk About Cost Discounts International Intellectual PropertyMedicare
Overview Part B
Part D
Center for Medicare andMedicaid Innovation
Medicine Safety
Overview Prescription Drug Misuse, Abuse & DisposalDrug
Importation
Drug Shortages
Research and DevelopmentOverview
Biologics & BiosimilarsClinical Trials
Corporate Venture CapitalFDA Modernization
PDUFA
Pediatrics Rare Diseases Regulatory Harmonization Vaccines The Value Collaborative340B
ADVOCACY
From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.340B | PhRMA
Part B | PhRMA
* Science
Overview Progress Treating DiseaseIn The Pipeline
Overview Medicines inDevelopment
Research in your BackyardClinical Trials
People Behind the ScienceSCIENCE
Today, cutting-edge medical science is transforming patients’ lives. Discover how scientists and researchers are advancing science. The 20-year journey yielding a new weapon against cancer | PhRMA Stopping the Spread of Ebola | PhRMA* Patients
Overview How Are Your Medicines Covered? Get Help WithYour Prescriptions
Access Patient ResourcesPATIENTS
Patient support and assistance is the top priority for PhRMA’s member companies, who are working hard to improve patients’ lives through the discovery and development of new medicines and treatments. Share the Savings | PhRMA Patient-Focused Drug Development | PhRMA* Resources
State Map Resource LibraryChart Packs
Industry Profile 2019RESOURCES
Explore the Resource Library, the interactive State Map and the ChartPack reports.
Press Room | PhRMA
Chart Packs | PhRMA
* Blog
*
__
* About
Back
ABOUT
PhRMA represents the country’s leading biopharmaceutical research companies and supports the search for new treatments and cures. Overview Our MissionOur Leadership
Members
Careers Events
Codes and Guidelines* Advocacy
Back
ADVOCACY
From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results. Overview Access to Medicines Overview Insurance CoverageMedicare
Access Better CoveragePatient Assistance
Medicaid
340B Drug Pricing
Program Cost and Value of Medicines Overview Let's Talk About Cost Discounts International Intellectual PropertyMedicare
Overview Part B
Part D
Center for Medicare andMedicaid Innovation
Medicine Safety
Overview Prescription Drug Misuse, Abuse & DisposalDrug
Importation
Drug Shortages
Research and DevelopmentOverview
Biologics & BiosimilarsClinical Trials
Corporate Venture CapitalFDA Modernization
PDUFA
Pediatrics Rare Diseases Regulatory Harmonization Vaccines The Value Collaborative340B
* Science
Back
SCIENCE
Today, cutting-edge medical science is transforming patients’ lives. Discover how scientists and researchers are advancing science. Overview Progress Treating DiseaseIn The
Pipeline
Overview Medicines inDevelopment
Research in your BackyardClinical Trials
People Behind the Science* Patients
Back
PATIENTS
Patient support and assistance is the top priority for PhRMA’s member companies, who are working hard to improve patients’ lives through the discovery and development of new medicines and treatments. Overview How Are Your Medicines Covered? Get Help WithYour Prescriptions
Access Patient Resources* Resources
Back
RESOURCES
Explore the Resource Library, the interactive State Map and the ChartPack reports.
Overview State Map
Resource Library
Chart Packs
Industry Profile 2019* Blog
* Our Network
Back
Welcome to the future of medicine. Where together, we go boldly.__ Learn More
Learn more about America's biopharmaceutical companies and how they seek to improve patients' lives.__ Learn More
A search engine designed to find resources available through the various biopharmaceutical industry programs.__ Learn More
Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.__ Learn More
There are right and wrong prescriptions for changing Medicare. Seniors need Washington to focus on the right ones.__ Learn More
The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.__ Learn More
We Work For Health aims to increase awareness by uniting workers throughout the industry.__ Learn More
* Members Site
* Press Room
* Events
* Stay Connected
Back
STAY CONNECTED
__
__
__
__
__
SIGN UP FOR UPDATES
__
__
-
FROM AROUND THE WEB
VOTE FOR CURES
__
-
FROM AROUND THE WEB
VOTE FOR CURES
Share This __ __ ____
__
-
FROM AROUND THE WEB
TOGETHER - MIGRAINE
__
-
FROM AROUND THE WEB
TOGETHER - MIGRAINE
Share This __ __ ____
__
-
FROM PHRMA
LET'S TALK ABOUT COST__
-
FROM PHRMA
LET'S TALK ABOUT COST Share This __ __ ____
__
-
FROM THE BLOG
NEW "PRESCRIPTION FOR MEDICARE" CAMPAIGN FOCUSES ON IMPACTS OF WRONG AND RIGHT SOLUTIONS FOR MEDICARE__
-
FROM THE BLOG
NEW "PRESCRIPTION FOR MEDICARE" CAMPAIGN FOCUSES ON IMPACTS OF WRONG AND RIGHT SOLUTIONS FOR MEDICARE Share This __ __ ____
__
-
FACT SHEET
PHRMA MEMBER COMPANIES RAISE CONCERNS WITH IMPACT OF PROPOSED INTERNATIONAL PRICING INDEX MODEL__
-
FACT SHEET
PHRMA MEMBER COMPANIES RAISE CONCERNS WITH IMPACT OF PROPOSED INTERNATIONAL PRICING INDEX MODEL Share This __ __ ____
‹›
The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers and biotechnology companies.LATEST FROM THE
BLOG
*
IP EXPLAINED: WILL AMERICA CEDE GLOBAL MEDICAL INNOVATION LEADERSHIPTO ASIA?
__by Megan Van Etten on September 18, 2019*
IP EXPLAINED: FOUR THINGS TO KNOW ABOUT THE BAYH-DOLE ACT __by Tom Wilbur on September 13, 2019*
HOSPITALS MAKE 9 TIMES MORE THAN PHYSICIANS’ OFFICES ON PROVIDER-ADMINISTERED MEDICINES __by Katie Koziara on September 10, 2019*
GUEST POST: FOLLOWING MY STROKE, HAVING ACCESS TO GROUND-BREAKING MEDICAL INNOVATION HAS NEVER BEEN MORE IMPORTANT __by Guest Contributor on September 4, 2019800
NEW MEDICINES & VACCINES are in clinical testing for cancerLearn More
550
NEW MEDICINES
Approved by the Food and Drug Administration since 2000.Learn More
$2.6
BILLION
The average cost to develop one new medicine.8
MONTHS
Priority FDA review time thanks to PDUFA73%
OF CANCER MEDICINES
in the pipeline, as of 2015, have the potential to be personalizedmedicines.
Learn More
171
MEDICINES IN DEVELOPMENTto treat diabetes
80+
AUTOIMMUNE DISEASES
have been identified to-date$3.5
MILLION
Average yearly amount PhRMA Foundation awards to young scientistsLearn More
7,000
NEW MEDICINES
Currently in development around the world.90%
OF ALL CLINICAL TRIALS are led by the biopharmaceutical industryLearn More
1 MILLION
PARTICIPANTS
were volunteering, in 2013, in clinical studies across the countryLearn More
100S
OF THOUSANDS
of clinical trials are currently ongoing or underwayLearn More
4.7
MILLION JOBS
are supported by America's biopharmaceutical companiesLearn More
45%
of all Medicare acute hospitals participate in 340B.Learn More
30,000
340B sites enrolled as of May 2015.Learn More
88%
DECLINE IN HIV/AIDS DEATH RATESSince the 1990s
80%
of 340B volume goes through DSH hospitals even though they make up just 9% of 340B entities.Learn More
1,500
NEW SAFE AND EFFECTIVE MEDICATIONS have been delivered to patients, thanks to PDUFA.Learn More
800
NEW MEDICINES & VACCINES are in clinical testing for cancerLearn More
550
NEW MEDICINES
Approved by the Food and Drug Administration since 2000.Learn More
$2.6
BILLION
The average cost to develop one new medicine.8
MONTHS
Priority FDA review time thanks to PDUFA73%
OF CANCER MEDICINES
in the pipeline, as of 2015, have the potential to be personalizedmedicines.
Learn More
171
MEDICINES IN DEVELOPMENTto treat diabetes
80+
AUTOIMMUNE DISEASES
have been identified to-date$3.5
MILLION
Average yearly amount PhRMA Foundation awards to young scientistsLearn More
7,000
NEW MEDICINES
Currently in development around the world.90%
OF ALL CLINICAL TRIALS are led by the biopharmaceutical industryLearn More
1 MILLION
PARTICIPANTS
were volunteering, in 2013, in clinical studies across the countryLearn More
100S
OF THOUSANDS
of clinical trials are currently ongoing or underwayLearn More
4.7
MILLION JOBS
are supported by America's biopharmaceutical companiesLearn More
45%
of all Medicare acute hospitals participate in 340B.Learn More
30,000
340B sites enrolled as of May 2015.Learn More
88%
DECLINE IN HIV/AIDS DEATH RATESSince the 1990s
80%
of 340B volume goes through DSH hospitals even though they make up just 9% of 340B entities.Learn More
1,500
NEW SAFE AND EFFECTIVE MEDICATIONS have been delivered to patients, thanks to PDUFA.Learn More
‹›
VIDEOS
__
-
Watch VideoBarriers to results-based contracts__
-
Watch Video
WHAT ARE RESULTS-BASED CONTRACTS?__
-
Watch Video
PRESCRIPTION DRUG SHORTAGES __VIEW MORE RESOURCESHIDE RESOURCES__
-
WATCH VIDEO
TOGETHER - CAR-T
__
-
WATCH VIDEO
INNOVATIONS IN MENTAL HEALTH CARE__
-
WATCH VIDEO
TOGETHER - MULTIPLE SCLEROSIS__
-
WATCH VIDEO
PRIORITIZING PATIENTS: A DISCUSSION ON OUTCOMES-BASED CARE__
-
WATCH VIDEO
TOGETHER - HIV/AIDS
__
-
WATCH VIDEO
INNOVATION SPOTLIGHT: COLLABORATION FUELING BIOPHARMACEUTICALADVANCEMENTS
__
-
WATCH VIDEO
WHAT'S THE DEAL WITH THESE PRESCRIPTION DRUG MIDDLEMEN?__
-
Watch This Video
CELLS - LEUKEMIA AND LYMPHOMA__
-
WATCH VIDEO
TOGETHER - ALS
__
-
WATCH VIDEO
HOW A RESEARCHER AND PATIENT ARE BATTLING CANCER TOGETHER__
-
WATCH VIDEO
MAPPING THE DEBATE / AT WHAT COST?+Share This
Share This
STAY
CONNECTED
__
*
MEMBERS SITE
*
Contact Us
*
Privacy Policy
*
Terms of Service
*
Site Map
Pharmaceutical Research and Manufacturers of America® 950 F Street, NW Suite 300, Washington, DC 20004 Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how we and third parties use pixel tags, and how that use affects you, visit our privacy policy andreview
"1. Information Collection."Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0